JP2006514989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514989A5 JP2006514989A5 JP2005506142A JP2005506142A JP2006514989A5 JP 2006514989 A5 JP2006514989 A5 JP 2006514989A5 JP 2005506142 A JP2005506142 A JP 2005506142A JP 2005506142 A JP2005506142 A JP 2005506142A JP 2006514989 A5 JP2006514989 A5 JP 2006514989A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- use according
- phenyl
- autoimmune
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*(C=C1)C=CC(OC2(*)*)=C1NC2=O Chemical compound C*(C=C1)C=CC(OC2(*)*)=C1NC2=O 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39967302P | 2002-07-29 | 2002-07-29 | |
| US44394903P | 2003-01-31 | 2003-01-31 | |
| US45233903P | 2003-03-06 | 2003-03-06 | |
| US10/631,029 US7517886B2 (en) | 2002-07-29 | 2003-07-29 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| PCT/US2003/024087 WO2004014382A1 (en) | 2002-07-29 | 2003-07-29 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010152958A Division JP5441841B2 (ja) | 2002-07-29 | 2010-07-05 | 2,4−ピリミジンジアミン化合物による自己免疫疾患の処置または予防の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006514989A JP2006514989A (ja) | 2006-05-18 |
| JP2006514989A5 true JP2006514989A5 (cg-RX-API-DMAC7.html) | 2010-08-19 |
Family
ID=31721742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005506142A Pending JP2006514989A (ja) | 2002-07-29 | 2003-07-29 | 2,4−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法 |
| JP2010152958A Expired - Fee Related JP5441841B2 (ja) | 2002-07-29 | 2010-07-05 | 2,4−ピリミジンジアミン化合物による自己免疫疾患の処置または予防の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010152958A Expired - Fee Related JP5441841B2 (ja) | 2002-07-29 | 2010-07-05 | 2,4−ピリミジンジアミン化合物による自己免疫疾患の処置または予防の方法 |
Country Status (24)
Families Citing this family (184)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| IL166241A0 (en) * | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| WO2004048343A1 (en) * | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| CL2004000303A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
| EP1648875A1 (en) * | 2003-07-30 | 2006-04-26 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
| ES2421139T3 (es) * | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| DK1663242T3 (da) * | 2003-08-07 | 2011-08-01 | Rigel Pharmaceuticals Inc | 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler |
| ATE542801T1 (de) * | 2003-08-15 | 2012-02-15 | Novartis Ag | Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine |
| AU2005231507B2 (en) | 2004-04-08 | 2012-03-01 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| JP4812763B2 (ja) | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ, インコーポレイテッド | シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途 |
| NZ588896A (en) | 2004-08-25 | 2012-05-25 | Targegen Inc | Heterocyclic compounds and methods of use |
| US20060058525A1 (en) * | 2004-09-01 | 2006-03-16 | Rajinder Singh | Synthesis of 2,4-pyrimidinediamine compounds |
| EP1805142A4 (en) | 2004-09-23 | 2009-06-10 | Reddy Us Therapeutics Inc | PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME |
| GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| ATE540035T1 (de) | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| MY169441A (en) * | 2004-12-08 | 2019-04-11 | Janssen Pharmaceutica Nv | 2,4, (4,6) pyrimidine derivatives |
| US7799778B1 (en) | 2005-01-12 | 2010-09-21 | Alcon, Inc. | 5-substituted 2-aminopyridine analogs for treating allergic and inflammatory diseases |
| US7713975B1 (en) | 2005-01-12 | 2010-05-11 | Alcon, Inc. | 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| JP5186219B2 (ja) | 2005-01-25 | 2013-04-17 | エピックス デラウェア, インコーポレイテッド | 置換アリールアミン化合物および5−ht6調節因子としてのその使用 |
| US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| JP2008540436A (ja) * | 2005-05-03 | 2008-11-20 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Jakキナーゼインヒビターおよびそれらの使用 |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| EP1896134A2 (en) * | 2005-06-13 | 2008-03-12 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
| EA015890B1 (ru) * | 2005-06-14 | 2011-12-30 | Тайджен Байотекнолоджи Ко. Лтд. | Производные пиримидина |
| ES2279500T3 (es) * | 2005-06-17 | 2007-08-16 | Magneti Marelli Powertrain S.P.A. | Inyector de carburante. |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| WO2007009681A1 (en) * | 2005-07-15 | 2007-01-25 | Glaxo Group Limited | 1 , 1-DIOXID0-2 , 3-DIHYDRO-l , 2-BENZISOTHIAZ0L-6-YL-1H-INDAZOL-4-YL-2 , 4-PYRIMIDINEDI AMINE DERIVATIVES |
| WO2007028445A1 (en) * | 2005-07-15 | 2007-03-15 | Glaxo Group Limited | 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives |
| US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007053452A1 (en) * | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US7713987B2 (en) * | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
| EP1959961A2 (en) * | 2005-12-06 | 2008-08-27 | Rigel Pharmaceuticals, Inc. | Formulation of insoluble small molecule therapeutics in lipid-based carriers |
| WO2007085540A1 (en) * | 2006-01-27 | 2007-08-02 | Glaxo Group Limited | 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives |
| KR101411695B1 (ko) * | 2006-02-17 | 2014-07-03 | 리겔 파마슈티칼스, 인크. | 자가면역 질환의 치료 또는 예방을 위한 2,4-피리미딘디아민 화합물 |
| WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| PE20080068A1 (es) | 2006-05-15 | 2008-03-17 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
| DK2089369T3 (da) | 2006-10-19 | 2011-05-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme |
| MX2009004426A (es) | 2006-10-23 | 2009-08-12 | Cephalon Inc | Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. |
| WO2008064274A1 (en) | 2006-11-21 | 2008-05-29 | Rigel Pharmaceuticals, Inc. | Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses |
| US7947698B2 (en) | 2007-03-23 | 2011-05-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| WO2008118823A2 (en) * | 2007-03-26 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| MX2009011199A (es) * | 2007-04-16 | 2010-03-17 | Hutchison Medipharma Entpr Ltd | Derivados de pirimidina. |
| DK2146779T3 (en) | 2007-04-18 | 2016-11-28 | Pfizer Prod Inc | Sulfonylamid derivatives to treat abnormal cell growth. |
| JP2010526048A (ja) * | 2007-05-04 | 2010-07-29 | アストラゼネカ アクチボラグ | アミノ−チアゾリル−ピリミジン誘導体、および癌の治療のための該誘導体の使用 |
| CN101903357A (zh) | 2007-07-17 | 2010-12-01 | 里格尔药品股份有限公司 | 作为pkc抑制剂的环状胺取代的嘧啶二胺 |
| EP2178870B1 (en) * | 2007-08-17 | 2018-09-19 | LG Chem, Ltd. | Indole and indazole compounds as an inhibitor of cellular necrosis |
| US20090088371A1 (en) * | 2007-08-28 | 2009-04-02 | Rigel Pharmaceuticals, Inc. | Combination therapy with syk kinase inhibitor |
| CA2710118A1 (en) | 2007-12-20 | 2009-07-02 | Cellzome Limited | Sulfamides as zap-70 inhibitors |
| AR070228A1 (es) | 2008-01-22 | 2010-03-25 | Dow Agrosciences Llc | Derivados de 5-fluoro pirimidina |
| HRP20170317T1 (hr) | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| US20110098288A1 (en) * | 2008-03-11 | 2011-04-28 | Jeremy Major | Sulfonamides as zap-70 inhibitors |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| KR20100132550A (ko) | 2008-04-16 | 2010-12-17 | 포톨라 파마슈티컬스, 인코포레이티드 | syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드 |
| US8063058B2 (en) | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
| BRPI0910668A2 (pt) * | 2008-04-22 | 2019-09-24 | Portola Pharmaceutiacals Inc | inibidores de proteína quinases |
| US7829574B2 (en) | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8426430B2 (en) | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| TW201008933A (en) | 2008-08-29 | 2010-03-01 | Hutchison Medipharma Entpr Ltd | Pyrimidine compounds |
| CN101659659B (zh) * | 2008-08-29 | 2013-01-02 | 和记黄埔医药(上海)有限公司 | 嘧啶衍生物及其医药用途 |
| EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
| CA2736258C (en) * | 2008-09-23 | 2016-11-29 | Rigel Pharmaceuticals, Inc. | Tricyclic carbamate jak inhibitors |
| EP2382210B1 (en) | 2008-12-30 | 2017-03-01 | Rigel Pharmaceuticals, Inc. | Pyrimidinediamine kinase inhibitors |
| WO2010090875A1 (en) | 2009-01-21 | 2010-08-12 | Rigel Pharmaceuticals, Inc. | Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases |
| PL2389372T3 (pl) | 2009-01-23 | 2016-02-29 | Rigel Pharmaceuticals Inc | Kompozycje i sposoby hamowania szlaku JAK |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Egfr 억제제 및 질환 치료방법 |
| WO2010129802A1 (en) * | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
| US20120172351A1 (en) | 2009-06-09 | 2012-07-05 | Nobuyuki Negoro | Novel fused cyclic compound and use thereof |
| EP2440534A2 (en) * | 2009-06-10 | 2012-04-18 | Cellzome Limited | Pyrimidine derivatives as zap-70 inhibitors |
| UA108077C2 (xx) | 2009-07-02 | 2015-03-25 | Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну | |
| EP2454265A2 (en) | 2009-07-17 | 2012-05-23 | Rigel Pharmaceuticals, Inc. | Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| MX337849B (es) * | 2009-07-28 | 2016-03-09 | Rigel Pharmaceuticals Inc | Composiciones y metodos para inhibicion de la via jak. |
| NZ623069A (en) | 2009-08-17 | 2015-11-27 | Sloan Kettering Inst Cancer | Heat shock protein binding compounds, compositions, and methods for making and using same |
| EP2501705B1 (en) | 2009-11-20 | 2014-08-27 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| US20110130415A1 (en) * | 2009-12-01 | 2011-06-02 | Rajinder Singh | Protein kinase c inhibitors and uses thereof |
| JP6067550B2 (ja) * | 2010-04-13 | 2017-01-25 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用 |
| BR112012029647A2 (pt) | 2010-05-21 | 2016-08-02 | Chemilia Ab | novos derivados de pirimidinas |
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| CA2801781C (en) | 2010-07-21 | 2018-02-27 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| KR101937495B1 (ko) | 2010-07-28 | 2019-01-10 | 리겔 파마슈티칼스, 인크. | Jak 경로의 억제를 위한 조성물 및 방법 |
| PH12013500246A1 (en) | 2010-08-10 | 2019-10-11 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
| AU2011323484B2 (en) | 2010-11-01 | 2016-10-06 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as Syk modulators |
| EP2975027A1 (en) | 2010-11-01 | 2016-01-20 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
| WO2012061415A1 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Oxypyrimidines as syk modulators |
| BR112013010564B1 (pt) | 2010-11-01 | 2021-09-21 | Celgene Car Llc | Compostos heterocíclicos e composições compreendendo os mesmos |
| JP5956999B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | ヘテロアリール化合物およびその使用 |
| AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| EP2637502B1 (en) | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
| MX343517B (es) | 2011-03-10 | 2016-11-07 | Rigel Pharmaceuticals Inc | 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide. |
| MX2013010898A (es) | 2011-03-24 | 2013-12-06 | Chemilia Ab | Novedoso derivados de la pirimidina. |
| US9249124B2 (en) | 2011-03-30 | 2016-02-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase inhibitors and methods of making and using thereof |
| TWI548621B (zh) * | 2011-04-22 | 2016-09-11 | 標誌製藥公司 | 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法 |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| SMT201900071T1 (it) | 2011-07-28 | 2019-02-28 | Rigel Pharmaceuticals Inc | Nuove formulazioni di (trimetossifenilammino)pirimidinile |
| BR112014003981A2 (pt) | 2011-08-23 | 2017-03-07 | Endo Pharmaceuticals Inc | compostos de pirimido-piridazinona e seu uso |
| JP2014532658A (ja) | 2011-10-28 | 2014-12-08 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | ブルトン型チロシンキナーゼ疾患または障害を治療する方法 |
| EP2782579B1 (en) | 2011-11-23 | 2019-01-02 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
| JP6317320B2 (ja) | 2012-03-15 | 2018-04-25 | セルジーン シーエーアール エルエルシー | 上皮成長因子受容体キナーゼ阻害剤の塩 |
| ES2880109T3 (es) | 2012-03-15 | 2021-11-23 | Celgene Car Llc | Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
| US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| US8946460B2 (en) | 2012-06-15 | 2015-02-03 | Commonwealth Scientific And Industrial Research Organisation | Process for producing polyunsaturated fatty acids in an esterified form |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| KR101446742B1 (ko) | 2012-08-10 | 2014-10-01 | 한국화학연구원 | N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| JP2015528501A (ja) | 2012-09-12 | 2015-09-28 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 白斑の治療法 |
| WO2014058921A2 (en) | 2012-10-08 | 2014-04-17 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| US9748604B2 (en) | 2012-10-19 | 2017-08-29 | The University Of North Carolina At Chapel Hill | Ion conducting polymers and polymer blends for alkali metal ion batteries |
| TWI638814B (zh) * | 2012-10-31 | 2018-10-21 | 富山化學工業股份有限公司 | 新穎之胺衍生物或其鹽 |
| EP2928891B1 (en) | 2012-12-04 | 2019-02-20 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| HK1218249A1 (zh) | 2013-01-25 | 2017-02-10 | Rigel Pharmaceuticals, Inc. | 用於治疗炎症性肠道疾病的化合物和方法 |
| CN105188371A (zh) | 2013-02-08 | 2015-12-23 | 西建阿维拉米斯研究公司 | Erk抑制剂及其用途 |
| US10130609B2 (en) | 2013-03-13 | 2018-11-20 | University Health Network | Pyrazole derivatives and their uses thereof |
| US9169249B2 (en) | 2013-03-14 | 2015-10-27 | Rigel Pharmaceuticals, Inc. | Protein kinase C inhibitors and uses thereof |
| KR20150139827A (ko) | 2013-04-01 | 2015-12-14 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 알칼리 금속 이온 배터리를 위한 이온 전도성 플루오로중합체 카르보네이트 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
| TWI667233B (zh) * | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
| EA201692155A1 (ru) | 2014-05-13 | 2017-04-28 | Мемориал Слоун-Кеттеринг Кэнсэ Сентр | МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| WO2016025561A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Forms and compositions of an erk inhibitor |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| EP3712134B1 (en) | 2014-12-16 | 2023-11-29 | Signal Pharmaceuticals, LLC | Salts of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide |
| US9513297B2 (en) | 2014-12-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-Jun N-terminal kinase in skin |
| EP3250557B1 (en) | 2015-01-29 | 2024-11-20 | Signal Pharmaceuticals, LLC | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| US10227288B2 (en) | 2015-02-03 | 2019-03-12 | Blue Current, Inc. | Functionalized fluoropolymers and electrolyte compositions |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| JP6853234B2 (ja) * | 2015-07-09 | 2021-03-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Btk阻害剤としてのピリミジン誘導体及びその使用 |
| EP3325432B1 (en) | 2015-07-24 | 2020-09-02 | Celgene Corporation | Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
| WO2017070796A1 (en) * | 2015-10-30 | 2017-05-04 | Trillium Therapeutics Inc. | Heterocycle derivatives and their use for the treatment of cns disorders |
| IL307931A (en) * | 2016-04-15 | 2023-12-01 | Epizyme Inc | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| CN110809471A (zh) | 2017-04-28 | 2020-02-18 | 阿沙纳生物科学公司 | 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| JP7311228B2 (ja) * | 2017-06-30 | 2023-07-19 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用 |
| CN107417611A (zh) * | 2017-07-25 | 2017-12-01 | 广州大学 | 一种3‑(4‑甲氧基苯基)‑6‑甲氧基‑4‑氯‑5,7‑二溴喹啉的合成方法 |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| CN111362928A (zh) * | 2018-12-26 | 2020-07-03 | 上海喆邺生物科技有限公司 | 2,4-二氨基嘧啶衍生物 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2020227549A1 (en) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
| US20200377518A1 (en) | 2019-05-29 | 2020-12-03 | Rigel Pharmaceuticals, Inc. | Method of preventing and treating thrombosis |
| WO2020257495A1 (en) * | 2019-06-18 | 2020-12-24 | Purdue Research Foundation | Inhibitors of erythrocyte band 3 tyrosine phosphorylation and uses thereof |
| AU2020300619A1 (en) | 2019-07-03 | 2022-01-27 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4009974A1 (en) | 2019-08-08 | 2022-06-15 | Rigel Pharmaceuticals, Inc. | Compounds and method for treating cytokine release syndrome |
| CA3147444A1 (en) | 2019-08-14 | 2021-02-18 | Rigel Pharmaceuticals, Inc. | Method of blocking or ameliorating cytokine release syndrome |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| CN110746402B (zh) * | 2019-09-21 | 2021-01-15 | 温州医科大学 | 一种2-n-芳基-4-n-芳基-5-氟嘧啶类化合物及其制备方法和应用 |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| KR102993352B1 (ko) | 2019-12-20 | 2026-07-22 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP2023518356A (ja) | 2020-03-12 | 2023-05-01 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Covid-19関連状態の治療のための方法 |
| GB202007903D0 (en) * | 2020-05-27 | 2020-07-08 | Univ Edinburgh | Method of producing macrophages |
| CN112920124B (zh) * | 2021-01-29 | 2024-03-01 | 安徽医科大学 | 一种嘧啶-2,4-二胺类化合物及其制备方法与应用 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為fgfr抑制劑之三環雜環 |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN116041263A (zh) * | 2023-01-03 | 2023-05-02 | 湖南吴赣药业有限公司 | 一种4-氨基-2,6-二氯嘧啶的合成方法 |
| KR20240156074A (ko) * | 2023-04-21 | 2024-10-29 | (주)엠디바이오팜 | Hpk1 및 mlk3 저해제 및 이를 함유하는 항암용 조성물 |
Family Cites Families (201)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3159547A (en) * | 1963-06-28 | 1964-12-01 | Abbott Lab | Method of lowering blood pressure with 4-(2-amino-4-pyrimidylamino)-benzene-sulfonamide |
| US3320256A (en) * | 1965-04-09 | 1967-05-16 | Hoffmann La Roche | Fluorinated imidazoo[1, 2-c]pyrimidines and pyrimido[1, 2-c]pyrimidines |
| GR80171B (en) | 1983-08-29 | 1985-01-02 | Ciba Geigy Ag | N-(2-nitrophenyl)-4-aminopyrimidine derivatives process for the preparation thereof and use |
| DE3618353A1 (de) | 1986-05-31 | 1987-12-03 | Hoechst Ag | Schaedlingsbekaempfungsmittel auf der basis von aminopyrimidin-derivaten sowie neue aminopyrimidin-verbindungen |
| DE3868287D1 (de) * | 1987-04-02 | 1992-03-19 | Ciba Geigy Ag | Reaktivfarbstoffe, deren herstellung und verwendung. |
| SU1499883A1 (ru) | 1987-11-24 | 1991-10-23 | Научно-исследовательский институт фармакологии АМН СССР | Дихлоргидрат 2,4-бис-(п-трет-бутиланилино)-5-окси-6-метилпиримидина, обладающий анальгетической и противовоспалительной активностью |
| HU206337B (en) * | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
| IE63502B1 (en) | 1989-04-21 | 1995-05-03 | Zeneca Ltd | Aminopyrimidine derivatives useful for treating cardiovascular disorders |
| US4983608A (en) * | 1989-09-05 | 1991-01-08 | Hoechst-Roussell Pharmaceuticals, Inc. | N-substituted-4-pyrimidinamines and pyrimidinediamines |
| US5179204A (en) * | 1989-09-05 | 1993-01-12 | Hoechst-Roussel Pharmaceuticals Incorporated | N-substituted-4-pyrimidinamines and pyrimidinediamines |
| JPH03127790A (ja) | 1989-10-11 | 1991-05-30 | Morishita Pharmaceut Co Ltd | N―(1h―テトラゾール―5―イル)―2―アニリノ―5―ピリミジンカルボキシアミド類及びその合成中間体 |
| TW224941B (cg-RX-API-DMAC7.html) | 1989-11-08 | 1994-06-11 | Yamanouchi Pharma Co Ltd | |
| GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
| DE4029650A1 (de) | 1990-09-19 | 1992-03-26 | Hoechst Ag | 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide |
| CA2074864A1 (en) | 1991-07-30 | 1993-01-31 | Carmen Almansa | Tetralones with pharmacological activity |
| US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| TW287160B (cg-RX-API-DMAC7.html) * | 1992-12-10 | 1996-10-01 | Hoffmann La Roche | |
| NZ274978A (en) * | 1993-10-12 | 1998-04-27 | Du Pont Merck Pharma | 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof |
| IL112290A (en) | 1994-01-12 | 1999-01-26 | Novartis Ag | Transformed aryl and the troiryl pyrimidines and herbicides containing them |
| US5585381A (en) * | 1994-06-01 | 1996-12-17 | Kureha Chemical Industry Co., Ltd. | Pyrimidine derivatives and pharmaceutical composition |
| US5733932A (en) * | 1995-01-06 | 1998-03-31 | The Picower Institute For Medical Research | Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions |
| GB9516121D0 (en) * | 1995-08-05 | 1995-10-04 | Pfizer Ltd | Organometallic addition to ketones |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| TW440563B (en) * | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
| GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
| US6004985A (en) * | 1996-10-09 | 1999-12-21 | Berlex Laboratories, Inc. | Thio acid derived monocylic N-heterocyclics as anticoagulants |
| DE19710435A1 (de) * | 1997-03-13 | 1998-09-17 | Hoechst Ag | Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen |
| GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| GB9723859D0 (en) | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Compound,composition and use |
| DE19750701A1 (de) * | 1997-11-15 | 1999-05-20 | Dystar Textilfarben Gmbh & Co | Verfahren zur Umsetzung von fluorsubstituierten Heterocyclen mit Aminen in Gegenwart von Phasentransfer-Katalysatoren |
| ATE401312T1 (de) * | 1997-12-15 | 2008-08-15 | Astellas Pharma Inc | Pyrimidin-5-carboxamid-derivate |
| AU754965B2 (en) | 1997-12-31 | 2002-11-28 | University Of Kansas, The | Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof |
| ATE245641T1 (de) * | 1998-02-17 | 2003-08-15 | Tularik Inc | Antivirale pyrimidinderivate |
| JP4499917B2 (ja) * | 1998-03-09 | 2010-07-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | インターロイキン−1β変換酵素のインヒビターとしての1,2−ジアゼパン誘導体 |
| WO1999047529A1 (en) | 1998-03-18 | 1999-09-23 | Ariad Pharmaceuticals, Inc. | Heterocyclic signal transduction inhibitors, compositions containing them |
| BRPI9909191B8 (pt) * | 1998-03-27 | 2021-07-06 | Janssen Pharmaceutica Nv | derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende |
| NZ506679A (en) | 1998-03-27 | 2002-11-26 | Janssen Pharmaceutica Nv | HIV inhibiting pyrimidine derivatives |
| GB9806739D0 (en) | 1998-03-28 | 1998-05-27 | Univ Newcastle Ventures Ltd | Cyclin dependent kinase inhibitors |
| WO1999050249A2 (en) * | 1998-04-01 | 1999-10-07 | Du Pont Pharmaceuticals Company | Pyrimidines and triazines as integrin antagonists |
| BR9910621A (pt) | 1998-05-22 | 2001-01-30 | Smithkline Beecham Corp | Novos compostos de imidazol 2-alquil substituìdos |
| US6093743A (en) * | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| JP2004504259A (ja) | 1998-06-30 | 2004-02-12 | パーカー ヒューズ インスティテュート | Jak−3インヒビターを用いたc−jun発現の阻害方法 |
| AU5682799A (en) | 1998-08-21 | 2000-03-14 | Parker Hughes Institute | Quinazoline derivatives |
| AU5438299A (en) | 1998-08-29 | 2000-03-21 | Astrazeneca Ab | Pyrimidine compounds |
| DE19851421A1 (de) | 1998-11-07 | 2000-05-11 | Boehringer Ingelheim Pharma | Neue Pyrimidine, deren Herstellung und Verwendung |
| ID28376A (id) | 1998-11-10 | 2001-05-17 | Janssen Pharmaceutica Nv | Pirimidina yang menghambat replikasi hiv |
| US6127376A (en) * | 1998-12-04 | 2000-10-03 | Berlex Laboratories, Inc. | Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| AU4157500A (en) | 1999-03-26 | 2000-10-16 | Astrazeneca Ab | Novel compounds |
| EP1165522A1 (en) | 1999-04-06 | 2002-01-02 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic thio substituted pyrimidines |
| DE19917785A1 (de) | 1999-04-20 | 2000-10-26 | Bayer Ag | 2,4-Diamino-pyrimidin-Derivate |
| AU5108000A (en) | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9918035D0 (en) | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
| DE19945982A1 (de) | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
| TR200200763T2 (tr) | 1999-09-24 | 2003-09-22 | Janssen Pharmaceutica N.V. | Antiviral bileşimler |
| AU7738000A (en) | 1999-09-30 | 2001-04-30 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
| AU1026901A (en) | 1999-10-29 | 2001-05-08 | Syngenta Participations Ag | Novel herbicides |
| AU4903201A (en) | 1999-11-30 | 2001-07-03 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
| OA12118A (en) | 1999-12-10 | 2006-05-04 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds. |
| US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| CA2396693A1 (en) * | 1999-12-28 | 2001-07-05 | Stephen T. Wrobleski | Cytokine, especially tnf-alpha, inhibitors |
| US6362172B2 (en) | 2000-01-20 | 2002-03-26 | Bristol-Myers Squibb Company | Water soluble prodrugs of azole compounds |
| KR20030024659A (ko) * | 2000-02-17 | 2003-03-26 | 암겐 인코포레이티드 | 키나제 억제제 |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| US6525051B2 (en) | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
| US7034019B2 (en) | 2000-05-08 | 2006-04-25 | Janssen Pharmaceutica N.V. | Prodrugs of HIV replication inhibiting pyrimidines |
| CA2406562C (en) | 2000-05-08 | 2009-09-15 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines and triazines |
| OA12292A (en) | 2000-06-26 | 2003-11-11 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents. |
| GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| DE60118576T2 (de) | 2000-08-18 | 2006-11-02 | 3M Innovative Properties Co., Saint Paul | Fluoro(meth)acrylatecopolymer-beschichtungsmassen |
| AU2001290912A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002022212A2 (en) * | 2000-09-18 | 2002-03-21 | Idec Pharmaceuticals Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| AU2001229722A1 (en) | 2000-11-29 | 2002-06-11 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
| US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| MXPA03005696A (es) | 2000-12-21 | 2003-10-06 | Glaxo Group Ltd | Pirimidinaminas como moduladores de angiogenesis. |
| BR0116493A (pt) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| WO2002060492A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
| AU2002258400A1 (en) | 2001-02-16 | 2002-08-28 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| BR0207096A (pt) | 2001-02-20 | 2004-01-20 | Astrazeneca Ab | Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3 |
| GB2373186A (en) | 2001-02-23 | 2002-09-18 | Astrazeneca Ab | Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation |
| MXPA03007621A (es) | 2001-02-23 | 2003-12-04 | Merck & Co Inc | Antagonistas nr2b de n-metil-d-aspartato no arilheterociclicos n-sustituidos. |
| ATE497603T1 (de) * | 2001-03-02 | 2011-02-15 | Gpc Biotech Ag | Drei-hybrid-assaysystem |
| IL159120A0 (en) | 2001-05-29 | 2004-05-12 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| WO2002096905A1 (en) | 2001-06-01 | 2002-12-05 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinases |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| MXPA03010961A (es) | 2001-05-31 | 2004-02-27 | Vertex Pharma | Compuestos de tiazol utiles como inhibidores de proteinas cinasas. |
| CA2450769A1 (en) | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| CA2450934A1 (en) | 2001-06-19 | 2002-12-27 | Marco Dodier | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| EP1408978A4 (en) | 2001-06-21 | 2005-07-13 | Ariad Pharma Inc | NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| HRP20031049A2 (en) | 2001-06-23 | 2004-06-30 | Aventis Pharma Inc | Pyrrolopyrimidines as protein kinase inhibitors |
| AU2002316421B2 (en) * | 2001-06-26 | 2008-05-15 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-ALPHA expression |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
| US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2003026665A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
| WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
| EP1453516A2 (de) * | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
| JP4460292B2 (ja) | 2001-10-17 | 2010-05-12 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法 |
| IL162210A0 (en) | 2001-11-28 | 2005-11-20 | Btg Int Ltd | Preventives or remedies for alzheimer's disease oramyloid protein fibrosis inhibitors containing ni trogen-containing heteroaryl |
| PY0228255A (es) | 2001-12-06 | 2004-06-01 | Pfizer Prod Inc | Compuestos cristalinos novedosos |
| SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
| WO2003055489A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| MXPA04007191A (es) | 2002-01-23 | 2005-03-31 | Bayer Pharmaceuticals Corp | Derivados de pirimidina como inhibidores de rho-quinasa. |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
| US7459455B2 (en) | 2002-02-08 | 2008-12-02 | Smithkline Beecham Corporation | Pyrimidine compounds |
| CA2477505A1 (en) | 2002-03-01 | 2003-09-12 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
| JP2005526765A (ja) * | 2002-03-11 | 2005-09-08 | シエーリング アクチエンゲゼルシャフト | Cdk−阻害性2−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用 |
| US7288547B2 (en) * | 2002-03-11 | 2007-10-30 | Schering Ag | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents |
| GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| GEP20074230B (en) | 2002-03-20 | 2007-11-12 | Bristol Myers Squibb Co | Phosphate prodrugs of fluorooxindoles |
| AU2003301758A1 (en) | 2002-05-06 | 2004-05-25 | Bayer Pharmaceuticals Corporation | Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders |
| WO2003095448A1 (en) | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| CN1665808A (zh) | 2002-05-06 | 2005-09-07 | 沃泰克斯药物股份有限公司 | 噻二唑或噁二唑及其作为jak蛋白激酶抑制剂的用途 |
| AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
| CA2487679A1 (en) | 2002-05-30 | 2003-12-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of jak and cdk2 protein kinases |
| AU2003276125B2 (en) | 2002-06-17 | 2007-05-17 | Smithkline Beecham Corporation | Chemical process |
| ES2373226T3 (es) * | 2002-06-28 | 2012-02-01 | Astellas Pharma Inc. | Derivado de diaminopirimidincarboxamida. |
| IL166241A0 (en) | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| WO2004014384A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| AU2003262642B2 (en) | 2002-08-14 | 2010-06-17 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| EP1562911B1 (en) | 2002-11-01 | 2010-01-06 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
| US7259161B2 (en) * | 2002-11-04 | 2007-08-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
| US7348335B2 (en) | 2002-11-05 | 2008-03-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
| GB0226582D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Anti-viral compounds |
| GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| RS20050380A (sr) | 2002-11-21 | 2007-11-15 | Pfizer Products Inc., | Derivati 3-aminopiperidina i postupci njihove proizvodnje |
| WO2004047843A1 (en) | 2002-11-26 | 2004-06-10 | Pfizer Products Inc. | Method of treatment of transplant rejection |
| WO2004048343A1 (en) | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| AU2002350719A1 (en) | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| JPWO2004054617A1 (ja) | 2002-12-13 | 2006-04-20 | 協和醗酵工業株式会社 | 中枢疾患の予防および/または治療剤 |
| US7226919B2 (en) | 2002-12-18 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Compositions useful as inhibitors of protein kinases |
| US7098332B2 (en) * | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| EP1597237B1 (en) | 2003-02-07 | 2016-07-27 | Janssen Pharmaceutica NV | Pyrimidine derivatives for the prevention of HIV infection |
| CL2004000303A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
| ES2325440T3 (es) | 2003-02-20 | 2009-09-04 | Smithkline Beecham Corporation | Compuestos de pirimidina. |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US20050009817A1 (en) | 2003-04-30 | 2005-01-13 | Jennifer Savoy | Substituted heteroaryls |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| EP1651595A2 (en) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| EP1651636A1 (en) | 2003-07-10 | 2006-05-03 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
| ES2317031T3 (es) | 2003-07-16 | 2009-04-16 | Janssen Pharmaceutica Nv | Derivados de triazolopirimidina como inhibidores de la glucogeno-sintasa-quinasa 3. |
| NZ545058A (en) | 2003-07-16 | 2008-05-30 | Janssen Pharmaceutica Nv | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| WO2005009980A1 (en) | 2003-07-22 | 2005-02-03 | Neurogen Corporation | Substituted pyridin-2-ylamine analogues |
| US7442698B2 (en) * | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| EP1648875A1 (en) | 2003-07-30 | 2006-04-26 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| DK1663242T3 (da) * | 2003-08-07 | 2011-08-01 | Rigel Pharmaceuticals Inc | 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler |
| ATE542801T1 (de) | 2003-08-15 | 2012-02-15 | Novartis Ag | Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine |
| US7223759B2 (en) | 2003-09-15 | 2007-05-29 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds |
| GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| AU2004272288B2 (en) | 2003-09-18 | 2008-11-13 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| WO2005027848A2 (en) | 2003-09-19 | 2005-03-31 | Barnes-Jewish Hospital | Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators |
| ES2361835T3 (es) | 2003-09-25 | 2011-06-22 | Janssen Pharmaceutica Nv | Derivados de purina inhibidores de la replicación del hiv. |
| DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| RU2006122853A (ru) | 2003-11-28 | 2008-01-10 | Новартис АГ (CH) | Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы |
| MY141255A (en) | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
| EP1694652A1 (en) * | 2003-12-19 | 2006-08-30 | Rigel Pharmaceuticals, Inc. | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
| ES2389203T3 (es) | 2004-01-12 | 2012-10-24 | Ym Biosciences Australia Pty Ltd | Inhibidores de quinasa selectivos |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| PL1713806T3 (pl) | 2004-02-14 | 2013-09-30 | Irm Llc | Związki i kompozycje jako inhibitory kinaz białkowych |
| US7607424B2 (en) * | 2004-02-17 | 2009-10-27 | Planet Eclipse Limited | Electro-magnetically operated rotating projectile loader |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| WO2005107760A1 (en) | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
| JP4812763B2 (ja) * | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ, インコーポレイテッド | シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途 |
| GB0419161D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| US20060047135A1 (en) | 2004-08-30 | 2006-03-02 | Chadwick Scott T | Process for preparing chloromethyl di-tert-butylphosphate |
| US20060058525A1 (en) * | 2004-09-01 | 2006-03-16 | Rajinder Singh | Synthesis of 2,4-pyrimidinediamine compounds |
| EP1794134A1 (de) | 2004-09-29 | 2007-06-13 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel |
| CA2584808A1 (en) | 2004-10-29 | 2006-05-11 | Rigel Pharmaceuticals, Inc. | Substituted pyridines with activity on syk kinase |
| ATE540035T1 (de) * | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| US7442716B2 (en) | 2004-12-17 | 2008-10-28 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
| US8211929B2 (en) | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| JP2008540436A (ja) * | 2005-05-03 | 2008-11-20 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Jakキナーゼインヒビターおよびそれらの使用 |
| US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| EP1896134A2 (en) * | 2005-06-13 | 2008-03-12 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
| EA200800285A1 (ru) | 2005-07-11 | 2008-08-29 | Санофи-Авентис | Новые производные 2,4-дианилинопиримидинов, их получение, лекарственные средства, фармацевтические композиции, содержащие указанные производные, и их применение, в частности, в качестве ингибиторов ikk |
| CA2616512A1 (en) | 2005-07-28 | 2007-02-08 | Intervet International B.V. | Novel benzimidazole (thio) carbamates with antiparasitic activity and the synthesis thereof |
| CN101282979B (zh) | 2005-09-13 | 2011-09-21 | 卫材R&D管理有限公司 | 稳定性被改善的含有磷酸氯甲酯衍生物的组合物及其制备方法 |
| WO2007053844A2 (en) * | 2005-10-31 | 2007-05-10 | Rigel Pharmaceuticals, Inc. | Compositions and methods for treating inflammatory disorders |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US7713987B2 (en) * | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
| TW200736232A (en) | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
| WO2007085540A1 (en) | 2006-01-27 | 2007-08-02 | Glaxo Group Limited | 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives |
| KR101411695B1 (ko) * | 2006-02-17 | 2014-07-03 | 리겔 파마슈티칼스, 인크. | 자가면역 질환의 치료 또는 예방을 위한 2,4-피리미딘디아민 화합물 |
| WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US7776855B2 (en) | 2006-07-27 | 2010-08-17 | Janssen Pharmaceutica N.V. | Antimicrobial oxazolidinone prodrugs |
-
2003
- 2003-07-29 IL IL16624103A patent/IL166241A0/xx unknown
- 2003-07-29 DE DE60330466T patent/DE60330466D1/de not_active Expired - Lifetime
- 2003-07-29 CA CA2492325A patent/CA2492325C/en not_active Expired - Lifetime
- 2003-07-29 WO PCT/US2003/024087 patent/WO2004014382A1/en not_active Ceased
- 2003-07-29 DK DK03784871.0T patent/DK1534286T3/da active
- 2003-07-29 NZ NZ537752A patent/NZ537752A/en not_active IP Right Cessation
- 2003-07-29 AT AT03784871T patent/ATE451104T1/de active
- 2003-07-29 BR BRPI0313059A patent/BR0313059B8/pt not_active IP Right Cessation
- 2003-07-29 RS YU20050069A patent/RS51752B/sr unknown
- 2003-07-29 JP JP2005506142A patent/JP2006514989A/ja active Pending
- 2003-07-29 CN CNA038211203A patent/CN1678321A/zh active Pending
- 2003-07-29 SG SG2007044290A patent/SG176311A1/en unknown
- 2003-07-29 US US10/631,029 patent/US7517886B2/en not_active Expired - Lifetime
- 2003-07-29 PL PL373455A patent/PL216744B1/pl unknown
- 2003-07-29 ES ES10010732.5T patent/ES2445208T3/es not_active Expired - Lifetime
- 2003-07-29 AU AU2003265336A patent/AU2003265336B8/en not_active Expired
- 2003-07-29 CN CN201310060555.0A patent/CN103169708B/zh not_active Expired - Lifetime
- 2003-07-29 IL IL166241A patent/IL166241A/en active IP Right Grant
- 2003-07-29 ES ES03784871T patent/ES2337782T3/es not_active Expired - Lifetime
- 2003-07-29 HR HRP20050089AA patent/HRP20050089B1/hr not_active IP Right Cessation
- 2003-07-29 MX MXPA05001096A patent/MXPA05001096A/es active IP Right Grant
- 2003-07-29 EP EP03784871A patent/EP1534286B1/en not_active Expired - Lifetime
-
2005
- 2005-01-27 IS IS7669A patent/IS2923B/is unknown
- 2005-01-27 SE SE0500203A patent/SE0500203L/sv not_active Application Discontinuation
- 2005-02-28 NO NO20051069A patent/NO332550B1/no not_active IP Right Cessation
-
2006
- 2006-10-05 US US11/539,101 patent/US7825116B2/en not_active Expired - Lifetime
-
2008
- 2008-02-08 US US12/028,581 patent/US7812029B1/en not_active Expired - Lifetime
-
2010
- 2010-01-21 US US12/691,657 patent/US8158621B2/en not_active Expired - Fee Related
- 2010-03-09 CY CY20101100217T patent/CY1110292T1/el unknown
- 2010-07-05 JP JP2010152958A patent/JP5441841B2/ja not_active Expired - Fee Related
-
2011
- 2011-08-11 IL IL214607A patent/IL214607A/en active IP Right Grant
-
2012
- 2012-03-13 US US13/418,696 patent/US8557806B2/en not_active Expired - Fee Related
-
2013
- 2013-05-24 RU RU2013123881A patent/RU2659777C9/ru active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2382211B1 (en) | Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists | |
| JP2007500722A5 (cg-RX-API-DMAC7.html) | ||
| CA2492325A1 (en) | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | |
| JP2011016800A5 (cg-RX-API-DMAC7.html) | ||
| WO2021008338A1 (zh) | 极光激酶抑制剂及其用途 | |
| CN114430740A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2010285441A5 (cg-RX-API-DMAC7.html) | ||
| WO2018022282A1 (en) | Novel therapeutic agents for the treatment of hbv infection | |
| CN101965345B (zh) | 吡啶化合物 | |
| WO2016071293A2 (en) | Pharmaceutical compound | |
| JP2008540637A5 (cg-RX-API-DMAC7.html) | ||
| EP2389377B1 (en) | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases | |
| JP2002543185A5 (cg-RX-API-DMAC7.html) | ||
| KR20170132204A (ko) | 신규 3-인돌 치환 유도체, 제약 조성물 및 사용 방법 | |
| TW201317231A (zh) | 經雜環取代之苯并呋喃衍生物及其用於治療病毒疾病之方法 | |
| HK1206031A1 (en) | Antibacterial compounds | |
| JP6386527B2 (ja) | カリウムイオンチャネル阻害剤としてのピロロピリダジン | |
| CA2983721A1 (en) | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same | |
| CN105073724A (zh) | 作为钾离子通道抑制剂的2,3-二氮杂萘类化合物 | |
| CA3113109A1 (en) | Monomer and multimeric anti-hbv agents | |
| KR20130108985A (ko) | (6,7-디히드로-2-니트로-5h-이미다졸[2,1-b][1,3]옥사진-6-일)아미드 화합물, 그의 제조방법 및 용도 | |
| EP2560969A1 (en) | 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists | |
| KR20190059983A (ko) | 2환성 함질소 헤테로환 유도체 및 그를 함유하는 의약 조성물 | |
| JP2019501896A (ja) | 抗菌化合物としての置換ベンザジノン | |
| JPH06507162A (ja) | 抗セロトニン類、それらの製造およびそれらを含有する薬物 |